Armed with fast track designation and solid Phase IIb data, Aurinia Pharmaceuticals Inc. will soon start a Phase III study of its sole asset voclosporin in treating lupus nephritis which the British Columbia-based group hopes will underpin a New Drug Application submission in early 2020.
The group's clinical strategy update on Nov. 3 came quickly after Aurinia 's end-of-Phase II meeting with the FDA. In...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)